Edition:
India

Blueprint Medicines Corp (BPMC.OQ)

BPMC.OQ on NASDAQ Stock Exchange Global Select Market

79.13USD
23 Apr 2018
Change (% chg)

$-2.83 (-3.45%)
Prev Close
$81.96
Open
$82.05
Day's High
$82.76
Day's Low
$78.67
Volume
142,991
Avg. Vol
176,018
52-wk High
$108.62
52-wk Low
$34.41

Chart for

About

Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug... (more)

Overall

Beta: --
Market Cap(Mil.): $2,592.25
Shares Outstanding(Mil.): 39.12
Dividend: --
Yield (%): --

Financials

High-flying biotech Loxo tempers bullish view for cancer drug

STAMFORD, Connecticut In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany's Bayer . Its stock tripled in the past year.

03 Apr 2018

BRIEF-Blueprint Medicines Q4 Loss Per Share $1.23

* BLUEPRINT MEDICINES REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

21 Feb 2018

BRIEF-Blueprint Medicines Prices Public Offering Of 3.70 Mln Shares At $81.00/Share

* BLUEPRINT MEDICINES ANNOUNCES PRICING OF PUBLIC OFFERING OF SHARES OF COMMON STOCK

13 Dec 2017

BRIEF-Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock

* BLUEPRINT MEDICINES ANNOUNCES PROPOSED PUBLIC OFFERING OF SHARES OF COMMON STOCK

12 Dec 2017

BRIEF-Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285

* Blueprint Medicines announces new data from ongoing phase 1 clinical trial of BLU-285 in patients with advanced gastrointestinal stromal tumors showing strengthened clinical activity across spectrum of kit and pdgfrα genotypes

10 Nov 2017

BRIEF-Thermo Fisher enters agreement with Blueprint Medicines​

* Thermo Fisher Scientific Inc - ‍ expanded development of Oncomine Dx Target Test by entering into an agreement with Blueprint Medicines Corporation​

31 Oct 2017

BRIEF-Blueprint Medicines Q3 loss per share $0.96

* Blueprint Medicines reports third quarter 2017 financial results

31 Oct 2017

Earnings vs. Estimates